GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy
13th March 2026 Uncategorised 0GSK has secured an FDA expansion for its respiratory syncytial virus vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green light puts GSK on a level playing field with Pfizer and Moderna, which secured endorsements for their RSV shots in 2025 and 2024, respectively.
More: GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy
Source: fierce